DB05451ExperimentalSmall molecule
P54 reduces the inflammation associated with cancer/tumors, Crohn's disease, inflammatory bowel disease, osteoarthritis, and ulcerative colitis. It inhibits the induction of the enzyme NFkB, thereby inhibiting downstream inflammatory genes such...
- Mechanism
- Curator reviewed
P54 inhibits the induction of the enzyme NFkB, thereby inhibiting downstream inflammatory genes such as COX II and iNOS.
- Primary indication
- Investigated for use/treatment in cancer/tumors (unspecified), crohn's disease, inflammatory bowel disease, osteoarthritis, and ulcerative colitis.Curator reviewed
Resolves to
Targets
What you can answer from here — as of April 02, 2025
2Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with P54, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account